Why prior auth is the hardest part of getting a GLP-1
The most common reason patients fail to start Wegovy, Zepbound, or Saxenda is not side effects, cost, or contraindications — it is an unfavorable prior authorization (PA) decision. Every major payer in the United States routes GLP-1 anti-obesity medication requests through PA, and denial rates for first-pass AOM submissions routinely exceed 50% on commercial plans. For Medicare Part D, anti-obesity GLP-1 coverage has historically been blocked by federal statute (MMA 2003, which excluded drugs for weight loss from Part D), though the 2024 SELECT-driven FDA label expansion for Wegovy created a pathway for cardiovascular-risk reduction in patients with established ASCVD.
The tool above estimates first-pass approval probability based on a points-based representation of typical 2026 PA criteria. Real plans use different templates — this is a ballpark, not your plan’s rubric.
What payers actually require — the documentation checklist
Most commercial PA templates for Wegovy or Zepbound ask for all of the following. Missing any one of them typically triggers a denial:
- Confirmed diagnosis with ICD-10 code in the chart note: E66.01 (morbid obesity), E66.9 (obesity, unspecified), or E11.xx (type 2 diabetes) for Ozempic/Mounjaro. ZZ codes or narrative alone are insufficient.
- Documented BMI ≥ 30, or ≥ 27 with a qualifying comorbidity: OSA (G47.33), hypertension (I10), type 2 diabetes (E11.9), dyslipidemia (E78.5), NAFLD/MASH (K75.81/K76.0), coronary artery disease (I25.10). Many plans accept PCOS (E28.2) and NAFLD; some do not.
- Documented prior weight-loss attempts: usually 3–6 months of structured diet and exercise within the past 1–2 years, with dates, type of intervention (WW, Noom, structured dietician program, bariatric counseling, etc.), and outcome. Vague “patient has tried diets” language is insufficient on most plans.
- Step therapy evidence: some plans require a failed trial of phentermine or orlistat before approving GLP-1. Others preferred Saxenda before Wegovy. Many have dropped step therapy as of 2024–2025 but not all.
- Contraindication screening: confirmation that patient does not have personal or family history of MTC or MEN2, is not pregnant (specific language for women of childbearing age), and is not on a contraindicated combination therapy.
- Specialist consult for certain plans: some plans require obesity medicine or endocrinology referral, not PCP.
Plan-type reality check
Approval rates vary wildly by plan category:
- Commercial fully-insured (BCBS, Aetna, Cigna, UnitedHealthcare): 50–80% of submitted AOM PAs approved first pass in 2025, per KFF and prescriber surveys. Plan-by-plan variance is enormous; a BCBS plan in Massachusetts looks nothing like one in Mississippi.
- Self-insured employer (ERISA plans): entirely dependent on the employer’s benefit design. Several Fortune 500 employers carved out AOM coverage entirely in 2023–2024 citing cost; others added coverage post-SELECT. Check your summary plan description (SPD) directly.
- Medicare Part D: does not cover AOMs (MMA exclusion). Does cover Ozempic for T2D. As of March 2024, Wegovy is covered for cardiovascular risk reduction in patients with established CVD and obesity/overweight (the SELECT indication). Tirzepatide/Zepbound: awaiting similar labeling.
- Medicaid: coverage varies by state. As of 2025, roughly 15 state Medicaid programs cover AOMs with PA; others do not.
- VA / TRICARE: VA covers semaglutide for T2D and, increasingly, Wegovy under formulary with restrictive criteria. TRICARE covers per formulary with PA.
Zepbound’s OSA indication as a PA lever
In December 2024, the FDA approved tirzepatide for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity — the first AOM with a sleep-apnea indication, based on SURMOUNT-OSA (N=469). AHI dropped 25–30 events/hour on tirzepatide vs 5–6 on placebo; 42% of tirzepatide patients achieved AHI < 5. For patients with documented moderate-severe OSA (AHI ≥ 15 by polysomnography or home sleep test), this creates a dedicated PA path for Zepbound: medical-necessity can be grounded in the OSA indication rather than the AOM indication, which has different coverage rules on many plans. A BMI ≥ 30 plus moderate-severe OSA is currently one of the highest first-pass approval scenarios on commercial plans. If you snore heavily, wake unrested, or have witnessed apneas, get a home sleep test before your Zepbound PA submission.
The appeal path when you get denied
A first-pass denial is not the end. Sequence:
- Read the denial letter carefully. It specifies which criterion was missed. Common denials: “insufficient documentation of prior diet”, “BMI below threshold”, “step therapy not completed”.
- Request peer-to-peer review. Your prescriber calls a plan medical director, usually within 5 business days. Peer-to-peer reverses a substantial fraction of denials where the denial was templated.
- File a formal appeal. Every plan must allow at least one internal appeal. Most require submission within 60–180 days. Include additional documentation, updated labs, worsening comorbidity data.
- External review. Each state has an independent external review process (per ACA section 2719) if internal appeals fail. An independent reviewer can overturn.
- Check employer benefits team. For self-insured ERISA plans, the employer can sometimes directly approve coverage or add a carve-out.
The SELECT cardiovascular indication — a new lever
In August 2023, results from the SELECT trial showed semaglutide 2.4 mg (Wegovy) reduced major adverse cardiovascular events (MACE) by 20% in patients with established CVD and BMI ≥ 27. In March 2024, the FDA added the cardiovascular risk reduction indication to the Wegovy label. This opens Medicare Part D coverage and strengthens commercial PA odds for patients with documented ASCVD — prior MI, prior stroke, prior TIA, peripheral arterial disease, or coronary/peripheral/carotid revascularization. If you qualify under SELECT criteria, ask your prescriber to cite the indication explicitly in the PA request. See the health savings tool for downstream economic value.
How trial eligibility translates to PA criteria
PA templates are essentially re-packaged trial-eligibility criteria plus managed-care step therapy. If your chart matches a trial cohort, your PA is dramatically more likely to approve. Quick map:
- STEP 1 (semaglutide 2.4 mg in non-diabetic obesity): adults ≥ 18, BMI ≥ 30 or ≥ 27 with weight-related comorbidity, no T2D, no prior bariatric surgery within past year. Wegovy PA criteria mirror this almost verbatim.
- SURMOUNT-1 (tirzepatide in non-diabetic obesity): same BMI thresholds. Zepbound PA criteria mirror SURMOUNT-1 eligibility.
- SELECT (semaglutide 2.4 mg CV indication): adults ≥ 45 with established CVD (prior MI, prior stroke, or symptomatic PAD) and BMI ≥ 27, no T2D. This is the Medicare Part D coverage pathway as of March 2024.
- SURPASS / SUSTAIN (T2D indications for Mounjaro, Ozempic): A1C ≥ 7.0%, T2D diagnosis (E11.x), typically on metformin first per ADA step-up. These PA approvals are much easier than anti-obesity PAs because Medicare and most commercial plans cover T2D GLP-1s as standard.
Pro tip for prescribers: when documenting, match the language of the pivotal trial. “Adult with BMI 32 and dyslipidemia, no T2D, prior 6-month supervised weight management program, appropriate candidate for chronic weight management per STEP 1” reads cleanly against a Wegovy template. “Patient wants Wegovy” does not.
Building the record before you submit
If your first-pass odds look low, invest 2–3 months strengthening the record before submitting:
- Schedule dietitian visits (often covered at $0 copay under ACA preventive) and document the attempt.
- Get a sleep study if you suspect OSA (BMI ≥ 30 + snoring + witnessed apneas is enough to test).
- Update labs — A1C, lipid panel, liver enzymes, BP — to capture comorbidities in writing.
- If BMI is 26.5, weigh in fasting and hydrated; BMI calculation is a snapshot, not a constant.
- Document every prior weight-loss attempt from the past 5 years with dates and outcomes.
FAQ
Does my HSA cover the cost if I skip PA and pay cash?
Yes. HSA and FSA funds can reimburse GLP-1 medications with a valid prescription regardless of insurance coverage. See the HSA/FSA calculator. Many patients pursue the dual path: file PA for coverage while buying via LillyDirect or NovoCare self-pay in the meantime.
My BMI is 27 and I have no comorbidity. What are my odds?
Low on commercial. You are at the floor for AOM eligibility and missing the comorbidity that most plans require. Options: (1) get screened for OSA, NAFLD, or pre-diabetes — any of these qualifies; (2) document prediabetic A1C (5.7–6.4%) if applicable; (3) pay cash via LillyDirect until you qualify.
Will my insurance drop my coverage after I lose weight?
Some plans apply continuation criteria at renewal — ongoing BMI ≥ threshold and ≥ 5% TBWL maintained. If you lose enough weight to fall below threshold, coverage can be discontinued. Read your plan’s continuation language carefully.
Does my PCP or an endocrinologist have better PA success?
Some plans require a specialist (endocrinology or obesity medicine). Most do not. An ABOM-certified obesity medicine physician often has better documentation habits that yield fewer denials.
Will the SELECT indication get Ozempic covered for heart disease?
Wegovy has the cardiovascular risk reduction indication, not Ozempic — even though they are the same molecule. Payers follow labels. Ask your prescriber to prescribe Wegovy for the CVD indication if you are ASCVD-eligible.
Does a FLOW-style CKD diagnosis help with PA?
For Ozempic in T2D patients with CKD, FLOW (2024) now underpins first-line GLP-1 preference in the ADA and KDIGO 2024–2025 guidelines. A chart that documents eGFR 30–60 mL/min/1.73 m² with albuminuria plus T2D should see very high Ozempic approval rates. For non-diabetic CKD, no AOM indication applies yet; appeal on individual merit.
What about STEP-HFpEF?
STEP-HFpEF (semaglutide 2.4 mg in HFpEF with obesity) has been incorporated into the 2025 AHA/ACC HFpEF guidance as a reasonable option for the obese HFpEF phenotype. Some commercial plans accept this as a comorbidity strengthener for Wegovy PAs; Medicare coverage for HFpEF indication is still through the SELECT CV-risk pathway if applicable.